In particular, one of the most successful clinical applications of immune checkpoint inhibitors includes antibodies directed against the programmed death protein 1 (PD-1) pathway, which inhibits cellular immune killing of cancer cells via complementary binding of tumor expressed programmed death ligand 1 (PD-L1) to PD-1 on immune cells (Pardoll, 2012). This evidence concerns the gene CD274 and cancer.